Presented in part at the 20th annual meeting of the Society of General Internal Medicine, Washington, DC, May 2, 1997.
Efficacy of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors for Prevention of Stroke
Article first published online: 25 DEC 2001
Journal of General Internal Medicine
Volume 14, Issue 12, pages 763–774, December 1999
How to Cite
Warshafsky, S., Packard, D., Marks, S. J., Sachdeva, N., Terashita, D. M., Kaufman, G., Sang, K., Deluca, A. J., Peterson, S. J. and Frishman, W. H. (1999), Efficacy of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors for Prevention of Stroke. Journal of General Internal Medicine, 14: 763–774. doi: 10.1046/j.1525-1497.1999.02109.x
- Issue published online: 25 DEC 2001
- Article first published online: 25 DEC 2001
- HMG-CoA reductase inhibitors;
- stroke prevention
OBJECTIVE: To determine if 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in preventing fatal and nonfatal strokes in patients at increased risk of coronary artery disease.
DESIGN: Meta-analysis of randomized controlled trials. Clinical trials were identified by a computerized search of medline (1983 to June 1996), by an assessment of the bibliographies of published studies, meta-analyses and reviews, and by contacting pharmaceutical companies that manufacture statins. Trials were included in the analysis if their patients were randomly allocated to a statin or placebo group, and reported data on stroke events. Thirteen of 28 clinical trials were selected for review. Data were extracted for details of study design, patient characteristics, interventions, duration of therapy, cholesterol measurements, and the number of fatal and nonfatal stroke events in each arm of therapy. Missing data on stroke events were obtained by contacting the investigators of the clinical trials.
MAIN RESULTS: Among 19,921 randomized patients, the rate of total stroke in the placebo group was 2.38% (90% nonfatal and 10% fatal). In contrast, patients who received statins had a 1.67% stroke rate. Using an exact stratified analysis, the pooled odds ratio (OR) for total stroke was 0.70 (95% confidence interval [CI] 0.57, 0.86; p= .0005). The pooled OR for nonfatal stroke was 0.64 (95% CI 0.51, 0.79; p= .00001), and the pooled OR for fatal stroke was 1.25 (95% CI 0.71, 2.24; p= .4973). In separate analyses, reductions in total and nonfatal stroke risk were found to be significant only for trials of secondary coronary disease prevention. Regression analysis showed no statistical association between the magnitude of cholesterol reduction and the relative risk for any stroke outcome.
CONCLUSIONS: The available evidence clearly shows that HMG-CoA reductase inhibitors reduce the morbidity associated with strokes in patients at increased risk of cardiac events. Data from 13 placebo-controlled trials suggest that on average one stroke is prevented for every 143 patients treated with statins over a 4-year period.